Accordingly, CD47-PD-L1-bispecific antibody PF-07257876 has entered a Phase I clinical trial for patients suffering from HNSCC, non-small cell lung cancer (NSCLC), and other PD-L1-positive carcinomas refractory and naïve to ICI (NCT04881045). The gene discussed is CD47; the disease is carcinoma.